We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+27.7%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$18.4B
AUM Growth
+$1.73B
Cap. Flow
-$958M
Cap. Flow %
-5.21%
Top 10 Hldgs %
90.4%
Holding
118
New
7
Increased
23
Reduced
7
Closed
13

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$60.8M
2
SWTX
SpringWorks Therapeutics
SWTX
+$35.8M
3
ROIV icon
Roivant Sciences
ROIV
+$33.4M
4
KYNB
Kyntra Bio
KYNB
+$26.7M
5
BPMC
Blueprint Medicines
BPMC
+$15M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$605M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$395M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$110M
4
TVTX icon
Travere Therapeutics
TVTX
+$25.8M
5
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$25.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.92%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMTX icon
26
Immatics
IMTX
$1.23B
$35.8M 0.19%
5,187,081
– –
ROIV icon
27
Roivant Sciences
ROIV
$23.6B
$35.3M 0.19%
4,777,430
+4,060,777
+567% +$33.4M
NRIX icon
28
Nurix Therapeutics
NRIX
$2.45B
$34.5M 0.19%
3,882,125
– –
KDNY
29
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$33.7M 0.18%
1,455,202
-1,078,900
-43% -$25.7M
KNSA icon
30
Kiniksa Pharmaceuticals
KNSA
$6.23B
$30.1M 0.16%
2,799,577
– –
DICE
31
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$29.7M 0.16%
1,035,786
+173,579
+20% +$5.14M
XENE icon
32
Xenon Pharmaceuticals
XENE
$6.1B
$26.9M 0.15%
751,639
– –
TSVT
33
DELISTED
2seventy bio
TSVT
$25.5M 0.14%
2,497,526
+434,782
+21% +$4.97M
DNLI icon
34
Denali Therapeutics
DNLI
$3.79B
$25.1M 0.14%
1,088,738
– –
DBVT
35
DBV Technologies
DBVT
$817M
$24.7M 0.13%
1,461,426
– –
KRYS icon
36
Krystal Biotech
KRYS
$10.7B
$24.2M 0.13%
302,716
– –
VERV
37
DELISTED
Verve Therapeutics
VERV
$20.4M 0.11%
1,416,530
– –
RARE icon
38
Ultragenyx Pharmaceutical
RARE
$2.46B
$18.9M 0.1%
470,974
– –
BCYC
39
Bicycle Therapeutics
BCYC
$269M
$17.9M 0.1%
843,814
– –
STOK icon
40
Stoke Therapeutics
STOK
$1.84B
$17.6M 0.1%
2,115,416
+1,006,503
+91% +$9.08M
ANAB icon
41
AnaptysBio
ANAB
$1.55B
$16.9M 0.09%
775,924
– –
RNAM
42
DELISTED
Avidity Biosciences
RNAM
$15.4M 0.08%
1,004,051
+569,269
+131% +$12.5M
BPMC
43
DELISTED
Blueprint Medicines
BPMC
$15M 0.08%
+333,665
New +$15M
SPRY icon
44
ARS Pharmaceuticals
SPRY
$579M
$13.1M 0.07%
2,006,451
– –
PACB icon
45
Pacific Biosciences
PACB
$438M
$13.1M 0.07%
1,127,782
– –
PRME icon
46
Prime Medicine
PRME
$549M
$12.7M 0.07%
1,028,466
– –
HRTX icon
47
Heron Therapeutics
HRTX
$94.5M
$12.3M 0.07%
8,131,678
– –
NVTA
48
DELISTED
Invitae Corporation
NVTA
$12M 0.07%
8,881,104
+479,069
+6% +$944K
IDYA icon
49
IDEAYA Biosciences
IDYA
$3.42B
$11.4M 0.06%
832,769
-835,586
-50% -$13.9M
CABA icon
50
Cabaletta Bio
CABA
$429M
$11.1M 0.06%
1,344,000
– –
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2023 Portfolio in Review

As of Q1 2023, Baker Bros. Advisors held 118 positions worth $18.4B, up 10% from $16.7B the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Baker Bros. Advisors withdrew a net $958M in Q1 2023, closing 13 positions and reducing 7 holdings. Its most notable exit was Ascendis Pharma A/S, an estimated $605M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

Against the trend, Baker Bros. Advisors opened a new position in Blueprint Medicines worth $15M.

  • Baker Bros. Advisors's largest Q1 2023 buy was Blueprint Medicines: 333,665 shares worth $15M.
  • Baker Bros. Advisors added most to Revolution Medicines in Q1 2023, an estimated $60.8M increase.
  • Baker Bros. Advisors's biggest Q1 2023 reduction was BioMarin Pharmaceuticals, cutting an estimated $395M.
  • Baker Bros. Advisors fully exited Ascendis Pharma A/S in Q1 2023, selling an estimated $605M.
  • Baker Bros. Advisors's ten largest holdings make up 90% of its $18.4B portfolio in Q1 2023.
  • Baker Bros. Advisors opened 7 new positions and closed 13 in Q1 2023.
  • Baker Bros. Advisors's portfolio value rose 10% quarter-over-quarter to $18.4B.

Based on Baker Bros. Advisors's 13F filing for Q1 2023, filed 15 May 2023.